The proportion of patients with diabetes that attained the double aim of HbA1c and the use of antidiabetic cardiovascular protective drugs (i.e., SGLT2i and GLP1-RA) was low in all groups, particularly in PAD patients. The gene discussed is GLP1R; the disease is diabetes mellitus.